Circulating VE-catherin and prognosis of cardiovascular events in remission of multiple myeloma
Objective. We aimed to evaluate the prognostic value of circulating VE-catherin for cumulative survival in patients with multiple myeloma in full or partial remission. Materials and methods. One hundred sixteen patients with multiple myeloma with complete or partial remission were enrolled in the...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporizhzhia State Medical and Pharmaceutical University
2016-06-01
|
| Series: | Zaporožskij Medicinskij Žurnal |
| Subjects: | |
| Online Access: | http://zmj.zsmu.edu.ua/article/view/76915/73858 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849744216245141504 |
|---|---|
| author | B. B. Samura |
| author_facet | B. B. Samura |
| author_sort | B. B. Samura |
| collection | DOAJ |
| description | Objective. We aimed to evaluate the prognostic value of circulating VE-catherin for cumulative survival in patients with multiple myeloma in full or partial remission.
Materials and methods. One hundred sixteen patients with multiple myeloma with complete or partial remission were enrolled in the study. Observation period was up to 3 years. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of VE-catherin was used.
Results and Conclusions. During observation period progression of multiple myeloma was proved in 41 patients, 6 persons were excluded for poor follow-up. One hundred ninety three cumulative clinical events occurred in 37 patients (53.6%) within the follow-up, with their distribution being as follows:14 cardiovascular deaths, 90 cardiac arrhythmias, 13 cardiac ischemic events, 6 strokes, 21 chronic heart failures and 49 hospital admissions for cardiovascular reasons. 28 deaths were not related with cardiovascular pathology.
Medians of circulating levels of VE-catherin in free-events subject cohort and subjects cohort with cardiovascular events were 0.51 ng/ml (95% confidence interval [CI]=0.21–0.81 ng/ml) and 1.30 ng/ml (95% CI=0.79–1.81 ng/ml) (р=0.02). In multivariate logistic regression circulating VE-catherin independently predicted cumulative cardiovascular events (odds ratio [OR] = 1.14; 95% CI=1.06–1.17; р=0.001) within 3 years of observation period.
Among patients with documented multiple myeloma in remission increased circulating VE-catherin associates with increased cumulative cardiovascular events.
VE-catherin; Cardiovascular Events; Multiple Myeloma; Survival; Prognosis |
| format | Article |
| id | doaj-art-eb9f74e8a34e4e4ca3ac13e8c81912b9 |
| institution | DOAJ |
| issn | 2306-4145 2310-1210 |
| language | English |
| publishDate | 2016-06-01 |
| publisher | Zaporizhzhia State Medical and Pharmaceutical University |
| record_format | Article |
| series | Zaporožskij Medicinskij Žurnal |
| spelling | doaj-art-eb9f74e8a34e4e4ca3ac13e8c81912b92025-08-20T03:21:16ZengZaporizhzhia State Medical and Pharmaceutical UniversityZaporožskij Medicinskij Žurnal2306-41452310-12102016-06-0131014Circulating VE-catherin and prognosis of cardiovascular events in remission of multiple myelomaB. B. SamuraObjective. We aimed to evaluate the prognostic value of circulating VE-catherin for cumulative survival in patients with multiple myeloma in full or partial remission. Materials and methods. One hundred sixteen patients with multiple myeloma with complete or partial remission were enrolled in the study. Observation period was up to 3 years. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of VE-catherin was used. Results and Conclusions. During observation period progression of multiple myeloma was proved in 41 patients, 6 persons were excluded for poor follow-up. One hundred ninety three cumulative clinical events occurred in 37 patients (53.6%) within the follow-up, with their distribution being as follows:14 cardiovascular deaths, 90 cardiac arrhythmias, 13 cardiac ischemic events, 6 strokes, 21 chronic heart failures and 49 hospital admissions for cardiovascular reasons. 28 deaths were not related with cardiovascular pathology. Medians of circulating levels of VE-catherin in free-events subject cohort and subjects cohort with cardiovascular events were 0.51 ng/ml (95% confidence interval [CI]=0.21–0.81 ng/ml) and 1.30 ng/ml (95% CI=0.79–1.81 ng/ml) (р=0.02). In multivariate logistic regression circulating VE-catherin independently predicted cumulative cardiovascular events (odds ratio [OR] = 1.14; 95% CI=1.06–1.17; р=0.001) within 3 years of observation period. Among patients with documented multiple myeloma in remission increased circulating VE-catherin associates with increased cumulative cardiovascular events. VE-catherin; Cardiovascular Events; Multiple Myeloma; Survival; Prognosishttp://zmj.zsmu.edu.ua/article/view/76915/73858VE-catherinCardiovascular EventsMultiple MyelomaSurvivalPrognosis |
| spellingShingle | B. B. Samura Circulating VE-catherin and prognosis of cardiovascular events in remission of multiple myeloma Zaporožskij Medicinskij Žurnal VE-catherin Cardiovascular Events Multiple Myeloma Survival Prognosis |
| title | Circulating VE-catherin and prognosis of cardiovascular events in remission of multiple myeloma |
| title_full | Circulating VE-catherin and prognosis of cardiovascular events in remission of multiple myeloma |
| title_fullStr | Circulating VE-catherin and prognosis of cardiovascular events in remission of multiple myeloma |
| title_full_unstemmed | Circulating VE-catherin and prognosis of cardiovascular events in remission of multiple myeloma |
| title_short | Circulating VE-catherin and prognosis of cardiovascular events in remission of multiple myeloma |
| title_sort | circulating ve catherin and prognosis of cardiovascular events in remission of multiple myeloma |
| topic | VE-catherin Cardiovascular Events Multiple Myeloma Survival Prognosis |
| url | http://zmj.zsmu.edu.ua/article/view/76915/73858 |
| work_keys_str_mv | AT bbsamura circulatingvecatherinandprognosisofcardiovasculareventsinremissionofmultiplemyeloma |